CXA-10
- Generic Name
- CXA-10
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H33NO4
- CAS Number
- 875685-46-4
- Unique Ingredient Identifier
- 1N19AGY57Y
- Background
CXA-10 is under investigation in clinical trial NCT03422510 (FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)).
- Associated Conditions
- -
- Associated Therapies
- -
Oral CXA-10 in Pulmonary Arterial Hypertension
- First Posted Date
- 2019-10-14
- Last Posted Date
- 2022-01-12
- Lead Sponsor
- Gladwin, Mark, MD
- Target Recruit Count
- 1
- Registration Number
- NCT04125745
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
CXA-10 Study in Subjects With Pulmonary Arterial Hypertension
- First Posted Date
- 2019-08-12
- Last Posted Date
- 2020-08-26
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT04053543
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Anti Inflammatory Lipid Mediators in Asthma Lipid Anti-Inflammtory Mediators in Asthma
- First Posted Date
- 2018-12-03
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- University of Colorado, Denver
- Target Recruit Count
- 60
- Registration Number
- NCT03762395
- Locations
- 🇺🇸
University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States
Anti-Inflammatory Lipid Mediators in Asthma
- First Posted Date
- 2018-09-21
- Last Posted Date
- 2018-09-21
- Lead Sponsor
- Sally E. Wenzel MD
- Registration Number
- NCT03680976
- Locations
- 🇺🇸
The University of Pittsburgh Asthma Institute at UPMC, Pittsburgh, Pennsylvania, United States
FIRSTx - A Study of Oral CXA-10 in Primary Focal Segmental Glomerulosclerosis (FSGS)
- First Posted Date
- 2018-02-05
- Last Posted Date
- 2020-08-03
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 33
- Registration Number
- NCT03422510
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Northwest Louisiana Nephrology, Shreveport, Louisiana, United States
🇺🇸St. Clair Nephrology Research, Roseville, Michigan, United States
A Study of the PK Interaction of CXA-10 With Pravastatin and Vytorin® in Healthy Males
- Conditions
- Interventions
- First Posted Date
- 2015-09-11
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 10
- Registration Number
- NCT02547402
- Locations
- 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States
PK and PD of Sequential Multiple Ascending, Repeat Doses of Oral CXA-10 in Healthy Obese Male Subjects
- First Posted Date
- 2015-06-02
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 43
- Registration Number
- NCT02460146
- Locations
- 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States
Oral CXA-10 Study in Healthy Volunteers
- First Posted Date
- 2014-12-09
- Last Posted Date
- 2016-05-03
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT02313064
- Locations
- 🇺🇸
Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States
Open-Label Safety, Tolerability, PK Study of IV CXA-10 Emulsion in Subjects in Chronic Kidney Injury
- First Posted Date
- 2014-09-25
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Complexa, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT02248051
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Jasper Clinical Research & Development, Inc., Kalamazoo, Michigan, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.